Under the agreement, Owens said the parties are pursuing a 12-month exclusive arrangement that includes revenue opportunities equating to approximately. Owens said the company expects that hitting the milestones could lead to “much bigger, broader, longer-term commercial deals” with IMV across the species Vitrafy is targeting. Medical device pathway and near-term milestonesOwens said some human health markets require medical device regulatory status, and that Vitrafy is working to accelerate commercialization in the research market while also pushing forward with medical device certification. He said the company has commenced its medical device program, beginning validation and verification work on the device. About Vitrafy Life Sciences (ASX:VFY)Recommended Stories